- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01947946
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Buenos Aires, Argentinië
- Research Site
-
Ciudad de Buenos Aire, Argentinië
- Research Site
-
-
-
-
-
São Paulo, Brazilië
- Research Site
-
-
-
-
-
Ruse, Bulgarije
- Research Site
-
Sofia, Bulgarije
- Research Site
-
Varna, Bulgarije
- Research Site
-
-
-
-
-
Hamburg, Duitsland
- Research Site
-
Mainz, Duitsland
- Research Site
-
-
-
-
-
Bydgoszcz, Polen
- Research Site
-
Giżycko, Polen
- Research Site
-
Lubin, Polen
- Research Site
-
Ostrów Wielkopolski, Polen
- Research Site
-
Warszawa, Polen
- Research Site
-
Wrocław, Polen
- Research Site
-
Łódź, Polen
- Research Site
-
Żnin, Polen
- Research Site
-
-
-
-
-
Chelyabinsk, Russische Federatie
- Research Site
-
Ekaterinburg, Russische Federatie
- Research Site
-
Izhevsk, Russische Federatie
- Research Site
-
Kazan, Russische Federatie
- Research Site
-
Moscow, Russische Federatie
- Research Site
-
Novosibirsk, Russische Federatie
- Research Site
-
Pyatigorsk, Russische Federatie
- Research Site
-
Saint Petersburg, Russische Federatie
- Research Site
-
St. Petersburg, Russische Federatie
- Research Site
-
Ulyanovsk, Russische Federatie
- Research Site
-
Vladikavkaz, Russische Federatie
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten
- Research Site
-
-
Arizona
-
Glendale, Arizona, Verenigde Staten
- Research Site
-
-
California
-
San Jose, California, Verenigde Staten
- Research Site
-
-
Colorado
-
Centennial, Colorado, Verenigde Staten
- Research Site
-
-
Florida
-
Miami, Florida, Verenigde Staten
- Research Site
-
Orlando, Florida, Verenigde Staten
- Research Site
-
Pembroke Pines, Florida, Verenigde Staten
- Research Site
-
Winter Park, Florida, Verenigde Staten
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, Verenigde Staten
- Research Site
-
Savannah, Georgia, Verenigde Staten
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Verenigde Staten
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten
- Research Site
-
-
Rhode Island
-
Warwick, Rhode Island, Verenigde Staten
- Research Site
-
-
South Carolina
-
Rock Hill, South Carolina, Verenigde Staten
- Research Site
-
-
Texas
-
Arlington, Texas, Verenigde Staten
- Research Site
-
Austin, Texas, Verenigde Staten
- Research Site
-
Dallas, Texas, Verenigde Staten
- Research Site
-
San Antonio, Texas, Verenigde Staten
- Research Site
-
Sugarland, Texas, Verenigde Staten
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Female and male aged from 18 to 75 years, inclusively
- History of physician-diagnosed asthma requiring treatment with medium dose ICS (>250ug fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
- Documented treatment with medium-dose ICS (>250ug and ≤500ug fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 month prior to Visit 1
Exclusion criteria:
- Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
- Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: - Affect the safety of the patient throughout the study - Influence the findings of the studies or their interpretations - Impede the patient's ability to complete the entire duration of study
- Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period 4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Benra 30 mg q.4 Weeks
Fixed 30 mg dose of benralizumab (every 4 weeks)
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Experimenteel: Benra 30 mg - Placebo q.8 Weeks
Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Placebo-vergelijker: Placebo
A (Dummy) injection
|
Placebo subcutaan in studieweek 0 tot en met studieweek 44.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Asthma Exacerbations Over 48 Weeks Treatment
Tijdsspanne: 48 weeks treatment
|
The number of asthma exacerbations over 48 weeks treatment will be counted
|
48 weeks treatment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: William W. Busse, MD, Allergy, Pulmonary and Critical Care Medicine, Clinical Science Center 600 Highland Ave, Madison, WI USA
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- D3250C00016
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië